A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases.
Andrea DuminucoElena TorreGiuseppe A PalumboClaire HarrisonPublished in: Current hematologic malignancy reports (2023)
In recent years, the advent of JAK inhibitors (JAKi) has significantly broadened treatment options for these patients. In myelofibrosis, symptom control and splenomegaly reduction can improve quality of life with improved overall survival, not impacting progression into acute leukaemia. Several JAKi are available and used worldwide, and combination approaches are now being explored. In this chapter, we review the approved JAKi, highlighting its strengths, exploring potential guidelines in choosing which one to use and reasoning towards future perspectives, where the combinations of therapies seem to promise the best results.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- liver failure
- prognostic factors
- patient reported
- drug induced
- clinical practice
- machine learning
- intensive care unit
- big data
- patient reported outcomes
- human health
- combination therapy
- aortic dissection
- smoking cessation
- mechanical ventilation